2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1452

Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Abstract Number: 192

Title: Use of Non-Traditional Modalities for Pain Management after Knee or Hip Joint Replacement
Abstract Number: 1722

TLR4 and TLR7 Are Required for Gadolinium Based Contrast Agent Induction of Dermal and Pulmonary Fibrosis in an Adenine-Induced Model of Chronic Renal Failure
Abstract Number: 2869

TLR7 Influences Autoreactive B Cell Selection in the Germinal Center
Abstract Number: 2274

TNF Inhibitors Provide Long-Term Clinical Benefits in 6 Patients with Early-Onset Sarcoidosis
Abstract Number: 1035

TNF-á Modulates the Expression of Circadian Clock Genes Via Calcium Signaling in Rheumatoid Synovial Cells
Abstract Number: 1516

TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis
Abstract Number: 1471

TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins
Abstract Number: 2729

To Live or Let Die… the Battle Between PD-1 and OX40 on SLE T Cells
Abstract Number: 1763

Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis
Abstract Number: 1233

Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever
Abstract Number: 1845

Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Abstract Number: 814

Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label Study of 22 Patients
Abstract Number: 2508

Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Abstract Number: 1912

Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].